Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Snap Inc SNAP

Snap Inc. is a technology company. Its product, Snapchat, is a visual messaging application that enhances relationships with friends, family, and the world. Snapchat is the Company's core mobile device application and contains five tabs, complemented by additional tools that function outside of the application. Snapchatters can interact with all five, or a subset of those five tabs. Additionally, the Company offers Snapchat+, its subscription product that provides subscribers access to exclusive, experimental, and pre-release features. Snapchat+ offers a range of features from allowing Snapchatters to customize the look and feel of their application, to giving special insights into their friendships. It also offers Snapchat for Web, a browser-based product that brings Snapchats calling and messaging capabilities to the Web. Its advertising products include AR Ads, AR Lenses and Snap Ads. Snap Ads include Single Image or Video Ads, Story Ads, Collection Ads, Dynamic Ads and Commercials.


NYSE:SNAP - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Veronson Apr 17, 2022 5:28am
127 Views
Post# 34608147

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS Video


FSD Pharma is delighted to announce pre-clinical findings indicating the efficacy of Lucid-MS, its flagship medication candidate, in treating Multiple Sclerosis. Lucid-MS's therapeutic potential is an industry first, and we'd like to provide visual evidence of functional recovery in pre-clinical individuals in this video!

<< Previous
Bullboard Posts
Next >>